Edit Entry

Christopher H. Lowrey, MD

Title(s):
Professor of Medicine
Professor of Pharmacology & Toxicology
Chief, Division of Hematology
Vice Chair, Department of Medicine

Department(s):
Medicine
Pharmacology & Toxicology

Education:
Boston University School of Medicine, MD 1985
University of Pennsylvania, MA 1981
Bowdoin College, BA 1979

Programs:
Norris Cotton Cancer Center
Pharmacology and Toxicology Graduate Program
Program in Experimental and Molecular Medicine
Other

Websites:
http://dms.dartmouth.edu/pharmtox/personnel/faculty/lowrey/
http://dms.dartmouth.edu/pemm/faculty/cancer_biology/
http://cancer.dartmouth.edu/blood_marrow/teamprofile/626/Christopher_H_Lowrey_MD
http://www.dhmc.org/webpage.cfm?site_id=2&org_id=2&morg_id=0&sec_id=16596&gsec_id=16596&item_id=626&utility_id=1&layer=0&parent_id=0&fuseaction=profile

Contact Information:

Christopher H. Lowrey, MD
Section of Hematology/Oncology
Dartmouth-Hitchcock Medical Center
Lebanon NH 03756

Office: 623 Rubin
Phone: 603-650-5747
Fax: 603-650-2334
Email: christopher.h.lowrey@dartmouth.edu

Assistant: Connie Goodrich
Asst. Phone: 603-650-2967
Asst. Email: Constance.M.Goodrich@hitchcock.org


Rotations and Thesis Projects:

Dr. Lowrey is not accepting rotation or thesis students for 2016-17.

Courses Taught:

Medical Pharmacology (Cancer Chemotherapy) - DMS 2
Scientific Basis of Medicine (Hematology) - DMS 2
Program in Experimental and Molecular Medicine

Biography:

Dr. Lowrey received his BA in Biochemistry from Bowdoin College in 1979 and his MA, also in Biochemistry, from the University of Pennsylvania in 1982. He received his MD from Boston University School of Medicine in 1985 and subsequently performed his residency in internal medicine at Tufts New England Medical Center in Boston and at the National Institutes of Health Clinical Center in Bethesda, MD. He then served as a Medical Staff Fellow and Senior Staff Fellow in the Clinical Hematology Branch of the National Heart, Lung, and Blood Institute of N.I.H. where he completed his fellowship in Hematology in 1992. In 1993 he joined the faculty of Dartmouth Medical School where he holds a joint appointment in the Departments of Medicine and Pharmacology.


Selected Publications:

 

Down the repressors! Up the fetal hemoglobin!
Lowrey CH
Blood. 2016 Mar 17;127(11):1384-5. doi: 10.1182/blood-2016-01-689018.
PMID: 26989189

Hospital readmission following transplantation: identifying risk factors and designing preventive measures.
McKenna DR, Sullivan MR, Hill JM, Lowrey CH, Brown JR, Hickman J, Meehan KR
J Community Support Oncol. 2015 Sep;13(9):316-22. doi: 10.12788/jcso.0168.
PMID: 26859751

Induction of fetal hemoglobin through enhanced translation efficiency of γ-globin mRNA.
Hahn CK, Lowrey CH
Blood. 2014 Oct 23;124(17):2730-4. doi: 10.1182/blood-2014-03-564302. Epub 2014 Aug 28.
PMID: 25170120

Multiple physical stresses induce γ-globin gene expression and fetal hemoglobin production in erythroid cells.
Schaeffer EK, West RJ, Conine SJ, Lowrey CH
Blood Cells Mol Dis. 2014 Apr;52(4):214-24. doi: 10.1016/j.bcmd.2013.10.007. Epub 2013 Dec 5.
PMID: 24314748

Laboratory tests for paroxysmal nocturnal hemoglobinuria.
Preis M, Lowrey CH
Am J Hematol. 2014 Mar;89(3):339-41. doi: 10.1002/ajh.23612.
PMID: 24127129

Vinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737.
Bates DJ, Danilov AV, Lowrey CH, Eastman A
Mol Cancer Ther. 2013 Aug;12(8):1504-14. doi: 10.1158/1535-7163.MCT-12-1197. Epub 2013 May 30.
PMID: 23723123

Eukaryotic initiation factor 2α phosphorylation mediates fetal hemoglobin induction through a post-transcriptional mechanism.
Hahn CK, Lowrey CH
Blood. 2013 Jul 25;122(4):477-85. doi: 10.1182/blood-2013-03-491043. Epub 2013 May 20.
PMID: 23690448

Simvastatin and t-butylhydroquinone suppress KLF1 and BCL11A gene expression and additively increase fetal hemoglobin in primary human erythroid cells.
Macari ER, Schaeffer EK, West RJ, Lowrey CH
Blood. 2013 Jan 31;121(5):830-9. doi: 10.1182/blood-2012-07-443986. Epub 2012 Dec 6.
PMID: 23223429

Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis.
Bates DJ, Salerni BL, Lowrey CH, Eastman A
Cancer Biol Ther. 2011 Aug 15;12(4):314-25. Epub 2011 Aug 15.
PMID: 21768777

Novel therapeutic candidates, identified by molecular modeling, induce γ-globin gene expression in vivo.
Boosalis MS, Castaneda SA, Trudel M, Mabaera R, White GL, Lowrey CH, Emery DW, Mpollo MS, Shen L, Wargin WA, Bohacek R, Faller DV, Perrine SP
Blood Cells Mol Dis. 2011 Aug 15;47(2):107-16. doi: 10.1016/j.bcmd.2011.04.008.
PMID: 21641240